Fosinopril sodium
Based on 3 publication(s) in Google Scholar
Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.20%
- CAS No.: 88889-14-9
- Formule: C30H45NNaO7P
- Masse moléculaire:585.64
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-B0279
RamiprilApoptosis Inducer -
HY-B0477
Quinapril hydrochlorideACE Inhibitor -
HY-B0368
CaptoprilACE Inhibitor -
HY-B0331A
Enalapril maleateAngiotensin-Converting Enzyme Inhibitor -
HY-B0331
EnalaprilAngiotensin-Converting Enzyme Inhibitor -
HY-B0093
BenazeprilACE Inhibitor -
HY-B0130
PerindoprilAngiotensin-converting enzyme Inhibitor -
HY-B0378A
Moexipril hydrochlorideACE Inhibitor -
HY-18206
LisinoprilACE Inhibitor -
HY-B0592
TrandolaprilACE Inhibitor -
HY-17505
Candesartan CilexetilAngiotensin II receptor Inhibitor -
HY-B0202
IrbesartanAT1 Receptor Blocker
Publications Citing Use of MedChemExpress (MCE) Fosinopril sodium
More
Activité biologique
Description
IC50 & Target
IC50: 0.18 μM; Ki: 1.675 μM
In Vitro
Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2[1]. Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2[1]. Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g) [3]
-
Dosage:4.67 mg/kg
-
Administration:p.o.; 4 weeks
-
Result:Against cardiac dysfunction and structural alteration and suppressed apoptosis.
Chemical Information
-
CAS No. 88889-14-9
-
Appearance Solid
-
Masse moléculaire 585.64
-
Formule C30H45NNaO7P
-
Color White to off-white
-
SMILES
O=C(O[Na])[C@H]1N(C(C[P@@](CCCCC2=CC=CC=C2)(O[C@H](OC(CC)=O)C(C)C)=O)=O)C[C@H](C3CCCCC3)C1
-
Synonyms
SQ28555
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
ACS Appl Mater Interfaces
Insights into the Mechanism of Supramolecular Self-Assembly in the Astragalus membranaceus- Angelica sinensis Codecoction. [Abstract]2023 Oct 18;15(41):47939-47954. PMID: 37791782 -
-
Solvant et solubilité
In Vitro:
H2O : 25 mg/mL (42.69 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 9.09 mg/mL (15.52 mM); Clear solution; Need ultrasonic
Protocole
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ondetti, M.A., Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation, 1988. 77(6 Pt 2): p. I74-8. [Content Brief]
[2]. Piepho, R.W., Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm, 2000. 57 Suppl 1: p. S3-7. [Content Brief]
[3]. Sharma, S., et al., The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther, 1999. 6(4): p. 181-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.7075 mL | 8.5377 mL | 17.0753 mL | 42.6883 mL |
| 5 mM | 0.3415 mL | 1.7075 mL | 3.4151 mL | 8.5377 mL | |
| 10 mM | 0.1708 mL | 0.8538 mL | 1.7075 mL | 4.2688 mL | |
| 15 mM | 0.1138 mL | 0.5692 mL | 1.1384 mL | 2.8459 mL | |
| 20 mM | 0.0854 mL | 0.4269 mL | 0.8538 mL | 2.1344 mL | |
| 25 mM | 0.0683 mL | 0.3415 mL | 0.6830 mL | 1.7075 mL | |
| 30 mM | 0.0569 mL | 0.2846 mL | 0.5692 mL | 1.4229 mL | |
| 40 mM | 0.0427 mL | 0.2134 mL | 0.4269 mL | 1.0672 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Fosinopril sodium Related Classifications
HY-B0382 Related Classifications
Powered by Bioz